Exclusive Summary

• **Differentiated Mechanism**: HER2 biparatopic ADC (targeting ECD2/ECD4) with superior receptor binding and internalization compared to standard mAbs, effective in low-expressing and resistant tumors.
• **Superior Safety Profile**: Addresses the critical limitation of the blockbuster competitor (DS-8201) with **zero reported cases of Interstitial Lung Disease (ILD)** across 440+ enrolled patients to date.
• **Excellent Efficacy**: Achieved an ORR of 61.5% in HER2-low breast cancer (outperforming historical data of competitors) and demonstrated durable potency in heavily pre-treated HER2-positive patients.
• **Leading Development Status**: One of the most advanced HER2 biparatopic ADCs globally, with three ongoing Phase III clinical trials covering breast and colorectal cancers.

Asset Materials

Contact Us for Full Materials